Open AccessCirculating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Author(s) -
Guillaume Herbreteau,
Audrey Vallée,
Sandrine Charpentier,
Nicola Normanno,
Paul Hofman,
Marc G. Denis
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2018.12.18
Subject(s) - circulating tumor dna , medicine , lung cancer , minimal residual disease , clinical practice , oncology , cell free fetal dna , dna , disease , cancer , cancer research , biology , family medicine , genetics , leukemia , pregnancy , fetus , prenatal diagnosis
Major advances in the treatment of non-small cell lung cancer (NSCLC) patients have been obtained during the last decade. Molecular testing of tumor samples is therefore mandatory in routine clinical practice. Tumor DNA is also present as cell-free molecules in blood, which is therefore a very useful and convenient source of tumor DNA. In this review, we discuss pre-analytical and analytical aspects of circulating tumor DNA (ctDNA) analysis. We also describe the use of ctDNA analysis in routine clinical practice, and discuss the potential use of ctDNA monitoring both to identify minimal residual disease and as a potential tool to early identify patients' response to treatment.